the aid library

LIST OPTIONS

Filter

2954

National Guidelines For Stem Cell Research

Indian Council of Medical Research & Department of Biotechnology (2017) C1

The guidelines reiterate that the general principles of ethics for biomedical research involving human participants shall also be applicable. In addition, the guidelines specify unique provisions for stem cells, because of their inherent property for unlimited proliferation, differentiation to cells... more

Download (156)

View PDF (362)

Antipsychotics and mood stabilizers in individuals with bipolar mania

World Health Organization WHO (2015) C_WHO

Q7: In individuals with bipolar mania, are a) antipsychotics, b) mood stabilizers (lithium carbonate, valproate, and carbamazepine) effective and safe

Download (159)

View PDF (246)

Epilepsy

World Health Organization (2004) C_WHO

Brief review of selected topics The following pages provide a focus on selected areas in relation to neurology. The specialists who contributed the reviews are listed in the Project Team and Partners Neurology Atlas (2004)

Download (149)

View PDF (248)

Role of neuroimaging in management of convulsive epilepsy

World Health Organization WHO (2012) C_WHO

Q6: What is the added advantage of doing neuroimaging in people with convulsive epilepsy in non-specialist settings in low and middle income countries?

Download (149)

View PDF (240)

Psychosocial interventions for the management of psychostimulant dependence (2015)

World Health Organization WHO mhGAP; WHO (2015) C_WHO

SCOPING QUESTION:Which psychosocial interventions are effective in the treatment of psychostimulant dependence for adults and young people?

Download (148)

View PDF (330)

Интеграция совместного оказания услуг в связи с ТБ и ВИЧ во всеобъемлющий пакет помощи для потребителей инъекционных наркотиков

World Health Organization WHO, THE END TB STRATEGY (2016) C_WHO

В основе настоящих руководящих принципов лежит структура организации мероприятий в соответствии с тремя задачами: • создание и укрепление механизмов комплексно... more

Download (171)

View PDF (185)

Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder

World Health Organization (2012) C_WHO

Q10: Are antidepressants (Tricyclic antidepressants (TCA), Selective serotonin reuptake inhibitors (SSRIs)) effective and safe in children 6-12 years of age with depressive episode/disorder?

Download (159)

View PDF (189)

Behaviour change techniques for promoting mental health

World Health Organization (2012) C_WHO

Q13: What is the effectiveness of behaviour change techniques including life skills education in promoting mental health for children and adolescents?

External Link

Treatment of anxiety disorders

B.Bandelo, S. Michaelis, D. Wedekind (2017) CC

Dialogues Clin Neurosci. 2017 Jun; 19(2): 93–107.

Download (238)

View PDF (184)

AIDSinfo Glossary of HIV/AIDS-Related Terms

AIDSinfo; National Library of Medicine (NIH); Department of Health & Human Services USA AIDSinfo; National Library of Medicine (NIH); Department of Health & Human Services USA (2018) C2

2018 9th Edition Offering information on HIV/AIDS treatment, prevention, and research

Updated Recommendations Onservice Delivery For The Treatment And Care Of People Living With HIV. Summary Slides
recommended

World Health Organization WHO (2021) C_WHO

These guidelines provide new and updated recommendations on the use of point-of-care testing in children under 18 months of age and point-of-care tests to monitor treatment in people living with HIV; the treatment monitoring algorithm; and timing of antiretroviral therapy (ART) among people living w... more

Hospital Level (Tertiary and Quaternary) Essential Medicines List | Reviewed items July 2021

National Department of Health South Africa National Department of Health South Africa (2021) C1

Reviewed Essential Medicines List July 2021

External Link

Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis

Singh-Phulgenda, S., Dahal, P., Ngu, R. et al. PLOS Neglected Tropical Diseases (2021) C1

Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported ... more

Download (145)

View PDF (174)

Medical treatment of cystic echinococcosis: systematic review and meta-analysis

Velasco-Tirado, V.; Alonso-Sardón, M.; Lopez-Bernus, A. et al BMC Infectious Diseases (2018) C2

Cystic echinococcosis (CE) is a well-known neglected parasitic disease. However, evidence supporting the four current treatment modalities is inadequate, and treatment options remain controversial. The aim of this work is to analyse the available data to answer clinical questions regarding medical t... more

Download (287)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (226)

View PDF (510)

Duration of antipsychotic treatment in individuals with long term and-or recurrent psychotic disorders

World Health Organization WHO (2012) C_WHO

Q4: In individuals with long term and/or recurrent psychotic disorders (including schizophrenia), should individuals be maintained on pharmacotherapy indefinitely or withdrawn from treatment in order to allow for the best outcomes?